Literature DB >> 2122926

Comparison of propranolol, diltiazem, and nifedipine in the treatment of ambulatory ischemia in patients with stable angina. Differential effects on ambulatory ischemia, exercise performance, and anginal symptoms. The ASIS Study Group.

P H Stone1, R S Gibson, S P Glasser, M A DeWood, J D Parker, D T Kawanishi, M H Crawford, F C Messineo, T L Shook, K Raby.   

Abstract

Episodes of transient myocardial ischemia during ambulatory activities are common in patients with stable coronary artery disease and who are often asymptomatic. Selection of therapy for episodes of asymptomatic ischemia is limited by a lack of direct comparative studies. To determine the most effective monotherapy for patients with stable angina and a high frequency of asymptomatic ischemic episodes, propranolol-LA (mean daily dose, 293 mg), diltiazem-SR (mean daily dose, 350 mg), nifedipine (mean daily dose, 79 mg) were each compared with placebo, each for 2 weeks, in a randomized, double-blinded, crossover trial. Entry criteria were a positive exercise treadmill test during placebo therapy characterized by 1.0 mm or more ST segment depression and angina pectoris, and six or more episodes of transient ST segment depression of 1.0 mm or more on a 48-hour ambulatory electrocardiogram. One hundred ninety-four patients were screened, 63 were eligible and received randomized therapy, of which 56 patients completed at least two of the four treatment periods and were included in an intent-to-treat analysis. Fifty patients completed all four treatment phases and were included in the protocol-completed analysis. Anti-ischemia efficacy was assessed by 48-hour ambulatory electrocardiographic monitoring, exercise treadmill tests, and anginal diaries. Ninety-four percent of all episodes of ambulatory ischemia were asymptomatic. Compared with placebo, only propranolol was associated with a marked reduction in all manifestations of asymptomatic ischemia during ambulatory electrocardiographic monitoring (2.3 versus 1.0 episodes/24 hr; mean duration of ischemia per 24 hours, 43.6 versus 5.7 minutes; both p less than 0.0001). Diltiazem's reduction of the frequency of episodes compared with placebo (2.3 versus 1.9 episodes/24 hr) was associated with a trend (p = 0.08) in the protocol-completed analysis and with a significant reduction in the intent-to-treat analysis (p = 0.03). Nifedipine had no significant effect on any measured variable of ambulatory ischemia. The dosages of medication used may have been excessive for some patients, and a more beneficial effect may have been evident at a lower dose. In contrast to the marked effects of the active agents on ambulatory asymptomatic ischemia, the effects on exercise performance and angina pectoris were slight. The active agents modestly improved treadmill exercise duration time until 1 mm ST segment depression (3%), and only propranolol and diltiazem had significant effects. Only diltiazem significantly prolonged the total exercise time. Anginal frequency was significantly decreased by both propranolol and diltiazem.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2122926     DOI: 10.1161/01.cir.82.6.1962

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  16 in total

1.  Investigation and management of stable angina: revised guidelines 1998. Joint Working Party of the British Cardiac Society and Royal College of Physicians of London.

Authors:  D de Bono
Journal:  Heart       Date:  1999-05       Impact factor: 5.994

Review 2.  Silent myocardial ischemia: recent developments.

Authors:  Peter F Cohn
Journal:  Curr Atheroscler Rep       Date:  2005-03       Impact factor: 5.113

Review 3.  Daily life cardiac ischaemia. Should it be treated?

Authors:  B D Bertolet; C J Pepine
Journal:  Drugs       Date:  1995-02       Impact factor: 9.546

4.  Sustained reduction of exercise perfusion defect extent and severity with isosorbide mononitrate (Imdur) as demonstrated by means of technetium 99m sestamibi.

Authors:  H C Lewin; R Hachamovitch; A G Harris; C Williams; J Schmidt; M Harris; K Van Train; G Siligan; D S Berman
Journal:  J Nucl Cardiol       Date:  2000 Jul-Aug       Impact factor: 5.952

Review 5.  Postinfarction use of beta-blockers in elderly patients.

Authors:  W S Aronow
Journal:  Drugs Aging       Date:  1997-12       Impact factor: 3.923

Review 6.  Silent myocardial ischaemia in the elderly.

Authors:  P C Deedwania
Journal:  Drugs Aging       Date:  2000-05       Impact factor: 3.923

7.  Angiotensin converting enzyme inhibition in chronic stable angina: effects on myocardial ischaemia and comparison with nifedipine.

Authors:  H Ikram; C J Low; T M Shirlaw; S G Foy; I G Crozier; A M Richards; N S Khurmi; R J Horsburgh
Journal:  Br Heart J       Date:  1994-01

Review 8.  Management of stable angina.

Authors:  A Jain; V Wadehra; A D Timmis
Journal:  Postgrad Med J       Date:  2003-06       Impact factor: 2.401

Review 9.  The management of ventricular arrhythmias in older patients after CAST.

Authors:  W S Aronow
Journal:  Drugs Aging       Date:  1995-02       Impact factor: 3.923

Review 10.  Calcium antagonists and silent myocardial ischaemia.

Authors:  G Steinbeck
Journal:  Drugs       Date:  1992       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.